4-Methoxyphencyclidine (methoxydine, 4-MeO-PCP) is a dissociative anesthetic drug that has been sold online as a research chemical. The synthesis of 4-MeO-PCP was first reported in 1965 by the Parke-Davis medicinal chemist Victor Maddox. A 1999 review published by a chemist using the pseudonym John Q.

Buy online: 4-MeO-PCP was the first arylcyclohexylamine research chemical to be sold online; it was introduced in late 2008 by a company trading under the name CBAY and was followed by several related compounds such as 3-MeO-PCP and methoxetamine. 4-MeO-PCP has lower affinity for the NMDA receptor than PCP but higher affinity than ketamine; it is orally active in a dosage range similar to ketamine, with some users requiring doses in excess of 100 mg for desired effects.

the 4-MeO-PCP has K_i values of 404 nM for the NMDA receptor, 713 nM for the norepinephrine transporter, 844 nM for the serotonin transporter, 296 nM for the σ₁ receptor, and 143 nM for the σ₂ receptor.

Legality

On October 18, 2012, the Advisory Council on the Misuse of Drugs in the United Kingdom released a report about methoxetamine, saying that the “harms of methoxetamine are commensurate with Class B of the Misuse of Drugs Act (1971),” despite the fact that the act does not classify drugs based on harm. The report went on to suggest that all analogues of MXE should also become class B drugs and suggested a catch-all clause covering both existing and unresearched arylcyclohexamines, including

Also see

• Arylcyclohexylamine
• 3-HO-PCP
• 3-MeO-PCE
• 3-MeO-PCMo
• 3-MeO-PCP
• MDPCP
• Methoxetamine
• Methoxyketamine